Specialized Oncology Focus Medelis, Inc. operates as a specialized oncology CRO with expertise spanning preclinical to late-phase clinical trials, indicating a strong position to attract sponsors seeking comprehensive oncology trial services in North America and Europe.

Recent Event Participation The company's active engagement in major industry events like BIO Europe 2025 and ASCO 2025 highlights its proactive approach to networking and visibility in the oncology research community, offering opportunities for outreach and partnership development.

Growth Through Merger The merger with WCCT in 2016 expanded Medelis’s service offering and geographic reach, suggesting potential for further growth and collaboration with clients looking for a broad and integrated clinical research partner.

Robust Revenue Base With annual revenues estimated between 25 and 50 million dollars, Medelis demonstrates financial stability and capacity to support large-scale oncology trials, making it an attractive partner for sponsors with significant clinical development budgets.

Advanced Industry Position Medelis’s focus on cutting-edge immunotherapy and complex oncology indications positions it as a leader in innovative cancer research, presenting opportunities to engage with biotech and pharma companies developing next-generation treatments.